Advantage Alpha Capital Partners LP Has $514,000 Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Advantage Alpha Capital Partners LP trimmed its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 42.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,151 shares of the biopharmaceutical company’s stock after selling 34,099 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Dynavax Technologies were worth $514,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Dynavax Technologies by 1.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 1,172 shares during the period. SummerHaven Investment Management LLC increased its position in shares of Dynavax Technologies by 2.4% in the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 1,303 shares during the period. Nisa Investment Advisors LLC raised its stake in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares in the last quarter. GAMMA Investing LLC raised its stake in Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in Dynavax Technologies by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock worth $740,000 after purchasing an additional 1,900 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DVAX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $12.66 on Wednesday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.66 billion, a PE ratio of 97.39 and a beta of 1.34. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $15.01. The business’s 50-day moving average price is $11.56 and its two-hundred day moving average price is $11.34.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.